Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Submitted by
admin
on April 13, 2023 - 11:50am
Source:
Motley Fool
News Tags:
Pfizer
GSK
Moderna Therapeutics
Headline:
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
snippet:
Pfizer, GSK, and Moderna are the leaders in the race to market RSV vaccines.
There's a serious unmet need with RSV causing health issues for older adults and children.
Pfizer should be a big winner in RSV, but it could have a lower market share than GSK.
Do Not Allow Advertisers to Use My Personal information
